Revelation Biosciences (FRA:56U0) Cash And Cash Equivalents : €13.39 Mil (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Revelation Biosciences Cash And Cash Equivalents?

Revelation Biosciences's quarterly cash and cash equivalents declined from Sep. 2023 (€13.11 Mil) to Dec. 2023 (€11.00 Mil) but then increased from Dec. 2023 (€11.00 Mil) to Mar. 2024 (€13.39 Mil).

Revelation Biosciences's annual cash and cash equivalents increased from Dec. 2021 (€1.13 Mil) to Dec. 2022 (€4.96 Mil) and increased from Dec. 2022 (€4.96 Mil) to Dec. 2023 (€11.00 Mil).

Revelation Biosciences Cash And Cash Equivalents Historical Data

The historical data trend for Revelation Biosciences's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Revelation Biosciences Cash And Cash Equivalents Chart

Revelation Biosciences Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

3.69

1.13

4.96

11.00

Revelation Biosciences Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash And Cash Equivalents	Get a 7-Day Free Trial								16.54	14.50	13.11	11.00	13.39

Revelation Biosciences Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Revelation Biosciences (FRA:56U0) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Revelation Biosciences Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Revelation Biosciences's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Revelation Biosciences (FRA:56U0) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Revelation Biosciences Inc (FRA:56U0) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

REVB:USA 56U1:Germany

Address

4660 La Jolla Village Drive, Suite 100, San Diego, CA, USA, 92122

Website

https://www.revbiosciences.com

Revelation Biosciences Inc is a clinical-stage life sciences company focused on the development of immunologic-based therapies for the prevention and treatment of disease. It has several product candidates in development. REVTx-99, the lead therapeutic candidate, is an intranasal immunomodulator to prevent or treat infections caused by various respiratory viruses such as SARS-CoV-2, including its variants, influenza A and B, parainfluenza, rhinovirus, and RSV. REVTx-99 is also being developed for other indications such as: allergic rhinitis and chronic nasal congestion. REVTx-200 is an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. REVTx-200 is based on the same technology used in REVTx-99.

Revelation Biosciences (FRA:56U0) Headlines

No Headlines